Planet Labs vs Regeneron Pharmaceuticals Inc — how do they compare? Planet Labs trades at $17.41 (market cap $6.46B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 11.8× Planet Labs's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Planet Labs pays none. Which is the better fit depends on your goals — on Pluang, investors hold Planet Labs for 4 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PL | REGN | |
|---|---|---|
Market Cap | $6.46B | $76.40B |
Volume | 10,188,839 | 626,381 |
Sector | Industrials | Health |
52-Week High | $51.40 | $852.03 |
52-Week Low | $11.16 | $557.73 |
Typical Hold Time | 4 Days | 107 Days |
Enterprise Value | $6.09B | $71.12B |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Planet Labs operates Earth-imaging satellites and provides geospatial data products. Its imagery and analytics help governments and businesses monitor changes across the planet.
Read more on PL →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →